Assembly Biosciences Research and Development Expenses 2010-2024 | ASMB

Assembly Biosciences research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Assembly Biosciences Annual Research and Development Expenses
(Millions of US $)
2023 $49
2022 $70
2021 $69
2020 $107
2019 $86
2018 $73
2017 $44
2016 $33
2015 $18
2014 $11
2013 $15
2012 $20
2011 $25
2010 $2
2009 $3
Assembly Biosciences Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $14
2024-06-30 $16
2024-03-31 $12
2023-12-31 $11
2023-09-30 $11
2023-06-30 $13
2023-03-31 $15
2022-12-31 $17
2022-09-30 $18
2022-06-30 $18
2022-03-31 $17
2021-12-31 $15
2021-09-30 $18
2021-06-30 $17
2021-03-31 $19
2020-12-31 $34
2020-09-30 $27
2020-06-30 $23
2020-03-31 $23
2019-12-31 $23
2019-09-30 $22
2019-06-30 $19
2019-03-31 $23
2018-12-31 $21
2018-09-30 $19
2018-06-30 $18
2018-03-31 $15
2017-12-31 $11
2017-09-30 $11
2017-06-30 $12
2017-03-31 $11
2016-12-31 $9
2016-09-30 $9
2016-06-30 $8
2016-03-31 $8
2015-12-31 $5
2015-09-30 $5
2015-06-30 $5
2015-03-31 $4
2014-12-31 $3
2014-09-30 $4
2014-06-30 $1
2014-03-31 $3
2013-12-31 $5
2013-09-30 $4
2013-06-30 $4
2013-03-31 $3
2012-12-31 $3
2012-09-30 $4
2012-06-30 $6
2012-03-31 $6
2011-12-31 $18
2011-09-30 $4
2011-06-30 $3
2011-03-31 $1
2010-12-31 $1
2010-09-30 $0
2010-06-30 $1
2010-03-31 $0
2009-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.098B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00